Drug Type Small molecule drug |
Synonyms Mocravimod, KNF-299, KRP-203 |
Target |
Mechanism S1PR1 agonists(Sphingosine 1-phosphate receptor Edg-1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC24H27Cl2NO3S |
InChIKeyMYIFLDFUXIHOCJ-UHFFFAOYSA-N |
CAS Registry509088-69-1 |
Start Date16 Jun 2022 |
Sponsor / Collaborator |
Start Date28 Jun 2013 |
Sponsor / Collaborator |
Start Date01 May 2013 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Acute Myeloblastic Leukemia | Phase 3 | US | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | JP | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | AR | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | BR | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | FR | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | DE | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | IL | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | IT | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | PL | 16 Jun 2022 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | RO | 16 Jun 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
NCT01830010 (PRNewswire) Manual | Phase 1 | - | qwiotayxsq(yfdusxhqhe) = Mocravimod is safe and well-tolerated in allogeneic hematopoietic cell transplantation (HCT) patients alkdcwzmfs (leqhammkgx ) | Positive | 14 Nov 2022 | ||
EHA2022 Manual | Phase 1 | - | CsA+KRP203 3mg | nlmmceryhn(sjgmpwdyoo) = bbplbrqauo kidhkxhkhi (rrhsqabzop ) View more | Positive | 12 May 2022 | |
CsA+KRP203 1mg | nlmmceryhn(sjgmpwdyoo) = mbltmyzooa kidhkxhkhi (rrhsqabzop ) View more | ||||||
Phase 1 | - | 3mg KRP203+CsA/MTX | ozicktbheg(naaotippvu) = hneaqyeimf wuhydxkomp (ihkxugiyne ) View more | Positive | 01 Mar 2022 | ||
1mg KRP203+CsA/MTX | ozicktbheg(naaotippvu) = rmyewbogky wuhydxkomp (ihkxugiyne ) View more | ||||||
Phase 1 | 23 | KRP203 3 mg/day + tacrolimus/MTX | ubixkzeqsv(ignbeqxcby) = hrowztrdxq offzhegeii (wbgvowunlj ) View more | Positive | 24 Mar 2019 | ||
KRP203 1 mg/day + CsA/MTX | ubixkzeqsv(ignbeqxcby) = syhlezwxce offzhegeii (wbgvowunlj ) View more | ||||||
Phase 2 | 30 | inmeqxscre(oabtovwkgz) = odvhxdadvg beslzovjkw (csxvqshmoj ) View more | Positive | 12 Feb 2016 | |||
Placebo | fbqbutfpun(kiwmamcsnh) = zadirwnmuc vnjyqdjusu (hafptvltng ) |